Welcome to Psychopathology and Treatment
Welcome to your study guide for Psychopathology and Treatment, a core component of Unit AS 4: Brain Science in CCEA Life and Health Sciences. In this chapter, we explore what happens when brain chemistry, structure, and neural pathways experience disruptions, leading to psychological and neurological conditions. We will also examine how modern pharmacotherapies (medications), psychological therapies, and advanced neuroimaging techniques work to diagnose, manage, and treat these conditions.
Don't worry if the neurobiology feels complex at first! We will break down each condition step-by-step, focusing on the underlying biology, key symptoms, and targeted treatments.
---1. Major Depressive Disorder (Unipolar Depression)
Major depressive disorder is more than just feeling sad; it is a clinical condition linked to measurable structural and neurochemical changes in specific brain networks.
A. The Monoamine Hypothesis
The monoamine hypothesis suggests that depression is caused by a functional deficit (depletion) of monoamine neurotransmitters at the synaptic cleft in key brain regions responsible for emotional processing, including the limbic system, hippocampus, and prefrontal cortex (PFC).
The three main monoamines involved are:
• Serotonin (\(5\text{-HT}\)): Regulates mood, sleep, appetite, and emotional stability.
• Noradrenaline (Norepinephrine): Influences alertness, energy, attention, and stress responses.
• Dopamine: Drives motivation, reward processing, and pleasure.
B. Neuroplasticity and Structural Changes
Modern neuroscience shows that depression is not simply an acute "chemical imbalance." It also involves structural and neuroplastic changes:
• Reduced Hippocampal Volume: Prolonged depressive states and chronic stress correlate with a measurable shrinkage in the hippocampus, a structure crucial for memory and emotional regulation.
• Altered Prefrontal Cortex Activity: Decreased activity and functional dysregulation in the prefrontal cortex impair decision-making and cognitive control over emotional responses.
• Decreased BDNF (Brain-Derived Neurotrophic Factor): Levels of BDNF, a vital neurotrophin responsible for neuronal survival, growth, and synaptic plasticity, are reduced.
C. Treatments for Depression
1. Selective Serotonin Reuptake Inhibitors (SSRIs):
Examples: Fluoxetine, Citalopram, Sertraline.
• Mechanism of Action: SSRIs selectively bind to and block the serotonin transporter (SERT) protein located on the presynaptic membrane. By preventing the reuptake (reabsorption) of serotonin back into the presynaptic neuron, SSRIs prolong the presence of \(5\text{-HT}\) in the synaptic cleft, increasing its availability to stimulate postsynaptic receptors.
• The Therapeutic Delay: Even though reuptake is blocked within hours, clinical improvements typically take 2 to 4 weeks. This delay occurs because the brain requires time to undergo downstream neuroplastic adaptations, including the down-regulation of inhibitory autoreceptors and increased BDNF expression.
2. Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs):
Examples: Venlafaxine, Duloxetine.
• Mechanism of Action: These medications inhibit the reuptake of both serotonin (\(5\text{-HT}\)) and noradrenaline, boosting the synaptic concentrations of both neurotransmitters across emotional circuits.
3. Cognitive Behavioural Therapy (CBT):
A structured psychological therapy that helps individuals identify and challenge maladaptive, negative cognitive biases and behavioural patterns. It is frequently combined with pharmacotherapy for enhanced long-term efficacy.
Common Exam Pitfall: Do not state that antidepressants work instantly because neurotransmitter levels rise quickly. Examiners expect you to acknowledge the 2 to 4 week therapeutic lag linked to receptor adaptation and neuroplasticity.
Key Takeaway for Depression: Depression involves reduced synaptic monoamines (\(5\text{-HT}\), noradrenaline), reduced BDNF, and structural changes in the hippocampus and PFC. SSRIs block the presynaptic SERT transporter to increase synaptic serotonin levels.
---2. Schizophrenia
Schizophrenia is a severe, chronic neurodevelopmental and psychiatric disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions.
A. Classification of Symptoms
To understand schizophrenia, you must clearly distinguish between positive and negative symptoms:
• Positive Symptoms (Added Experiences): Behaviors or experiences that are present in patients but absent in healthy individuals. These include hallucinations (e.g., hearing voices), delusions (firmly held false beliefs), and thought disorder (disorganized thinking and speech).
• Negative Symptoms (Deficits/Loss of Function): Characteristics that represent a reduction or loss of normal functioning. These include alogia (poverty of speech), flat affect (diminished emotional expression), avolition (lack of motivation and goal-directed activity), and anhedonia (inability to feel pleasure).
Memory Trick: Think of Positive as an "added extra" (like hearing extra voices) and Negative as a "subtraction" (subtracting normal emotional expression or speech).
B. The Dopamine Hypothesis and Brain Pathways
The dopamine hypothesis links schizophrenia to pathway-specific abnormalities in dopamine neurotransmission:
• Mesolimbic Pathway (Hyperdopaminergic Activity): An excessive release of dopamine or hyperactive \(D_2\) receptor transmission in the mesolimbic circuit leads to positive symptoms (hallucinations and delusions).
• Mesocortical Pathway / Prefrontal Cortex (Hypodopaminergic Activity): A deficit or underactivity of dopamine transmission projecting to the prefrontal cortex is responsible for negative symptoms and cognitive deficits.
C. Structural and Neurodevelopmental Markers
Neuroimaging and post-mortem studies reveal distinct structural abnormalities in the brains of individuals with schizophrenia:
• Enlarged Lateral Ventricles: Fluid-filled spaces in the brain expand, reflecting loss of surrounding neural tissue.
• Cortical Gray Matter Reduction: Widespread thinning and loss of gray matter volume, particularly in frontal and temporal regions.
• Abnormal Synaptic Pruning: Excessive or aberrant elimination of synaptic connections during late adolescence and early adulthood.
D. Pharmacological Treatments (Antipsychotics)
1. Typical (First-Generation) Antipsychotics:
Examples: Haloperidol, Chlorpromazine.
• Mechanism: Act as high-affinity antagonists at dopamine \(D_2\) receptors, blocking dopamine action primarily in the mesolimbic system to reduce positive symptoms.
• Limitations & Side Effects: Because they non-selectively block \(D_2\) receptors across the brain (including the nigrostriatal motor pathway), they carry a high risk of extrapyramidal side effects (EPS) such as tremors, muscle rigidity, and long-term tardive dyskinesia (involuntary repetitive movements).
2. Atypical (Second-Generation) Antipsychotics:
Examples: Clozapine, Risperidone, Olanzapine.
• Mechanism: Act as dual antagonists, blocking both dopamine \(D_2\) receptors and serotonin \(5\text{-HT}_{2A}\) receptors.
• Advantages & Limitations: They carry a significantly lower risk of motor extrapyramidal side effects and are more effective at addressing some negative symptoms. However, they require careful monitoring for metabolic side effects (e.g., rapid weight gain, elevated blood glucose) and rare blood disorders such as agranulocytosis (severe drop in white blood cell count, particularly associated with Clozapine).
Key Takeaway for Schizophrenia: Positive symptoms stem from mesolimbic hyperdopaminergic activity (\(D_2\)), while negative symptoms involve mesocortical hypodopaminergic activity. Typical antipsychotics block \(D_2\) receptors; atypical antipsychotics block both \(D_2\) and \(5\text{-HT}_{2A}\) receptors.
---3. Dementia and Neurodegenerative Conditions (Alzheimer's Disease)
Dementia is an umbrella clinical syndrome characterized by progressive cognitive decline that interferes with daily living. Alzheimer's disease is the most common underlying cause of dementia.
A. Neuropathological Hallmarks of Alzheimer's Disease
Alzheimer's disease is characterized by two distinct microscopic protein abnormalities alongside macroscopic tissue death:
• Extracellular Amyloid-Beta (\(\text{A}\beta\)) Plaques: Dense deposits of insoluble \(\text{A}\beta\) peptides that accumulate outside neurons, disrupting cell-to-cell signalling and provoking inflammatory responses.
• Intracellular Neurofibrillary Tangles (NFTs): Accumulations of abnormally hyperphosphorylated tau protein inside neurons. Normally, tau stabilizes axonal microtubules (the cellular skeleton/transport system). When hyperphosphorylated, tau detaches and tangles, causing internal cell collapse and neuronal death.
• Progressive Cortical Atrophy: Severe shrinkage of brain tissue that characteristically starts in the entorhinal cortex and hippocampus (causing early memory loss) and gradually spreads across the temporal and parietal lobes.
B. The Cholinergic Hypothesis
The cholinergic hypothesis highlights the profound degeneration of cholinergic (acetylcholine-producing) neurons located in the nucleus basalis of Meynert. This causes a dramatic depletion of acetylcholine (ACh), a neurotransmitter essential for learning, attention, and memory formation.
C. Pharmacological Treatments for Alzheimer's Disease
Currently available medications manage symptoms and slow cognitive decline rather than curing the underlying pathology:
1. Cholinesterase Inhibitors (AChEIs):
Examples: Donepezil, Rivastigmine, Galantamine.
• Mechanism: Inhibit the enzyme acetylcholinesterase (AChE), which is responsible for breaking down acetylcholine in the synaptic cleft. This increases the concentration and residence time of surviving ACh molecules at postsynaptic receptors, temporarily boosting cognitive performance.
2. NMDA Receptor Antagonists:
Example: Memantine.
• Mechanism: Blocks N-methyl-D-aspartate (NMDA) receptors against excessive, toxic levels of glutamate stimulation (a process known as excitotoxicity), protecting surviving cortical and hippocampal neurons from calcium-mediated damage.
Key Takeaway for Alzheimer's: Look for extracellular amyloid-beta (\(\text{A}\beta\)) plaques, intracellular hyperphosphorylated tau tangles, and loss of acetylcholine neurons from the nucleus basalis of Meynert. Treatments include acetylcholinesterase inhibitors (e.g., Donepezil) and NMDA antagonists (Memantine).
---4. Neuroscientific Investigation Techniques
To assess, diagnose, and monitor psychopathology and neurodegeneration, researchers and clinicians rely on three major categories of neuroimaging and electrophysiological tools.
A. Structural Imaging Techniques
These methods capture high-resolution, static anatomical images of the brain's physical architecture:
• Structural Magnetic Resonance Imaging (MRI): Uses strong magnetic fields and radiofrequency pulses to generate highly detailed cross-sectional images (e.g., T1-weighted scans showing structural detail, and T2-weighted scans showing fluid accumulation). Used to measure hippocampal atrophy in Alzheimer's or cortical thinning.
• Computed Tomography (CT) Scans: Employs a series of rotated X-ray beams to produce 2D slice images. Useful for rapidly identifying large structural changes, enlarged lateral ventricles in schizophrenia, gross brain shrinkage, or acute vascular lesions.
B. Functional Imaging Techniques
These techniques measure dynamic, real-time physiological activity, blood flow, or chemical receptor binding:
• Functional Magnetic Resonance Imaging (fMRI): Detects changes in blood oxygen levels across brain regions using the Blood Oxygen Level Dependent (BOLD) signal. Active brain areas demand more oxygenated blood, allowing researchers to map altered prefrontal cortex or limbic activation during cognitive and emotional tasks.
• Positron Emission Tomography (PET): Involves injecting a tiny, safe amount of a radioactive tracer (radioligand) into the bloodstream.
Key Radioligands:
1. Fluorodeoxyglucose (\([^{18}\text{F}]\text{-FDG}\)): A radioactive glucose analogue that tracks regional metabolic glucose consumption, highlighting areas of hypometabolism in degenerative disorders.
2. Amyloid Tracers: Radioligands engineered to bind selectively to amyloid-beta deposits, confirming the presence of plaques in Alzheimer's disease.
C. Electrophysiology
• Electroencephalography (EEG): Uses non-invasive scalp electrodes to record the collective electrical oscillations (voltage fluctuations) generated by millions of firing cortical neurons. EEG provides exceptional millisecond-level temporal resolution to monitor abnormal brain wave patterns and sleep cycle disturbances associated with psychiatric conditions.
Key Takeaway for Neuroimaging: Structural scans (CT, MRI) show physical brain anatomy, while functional scans (fMRI BOLD, PET with \([^{18}\text{F}]\text{-FDG}\)) and electrophysiology (EEG) measure active metabolism, blood flow, receptor binding, and electrical oscillations.
---Quick Comparison Summary Table
• Unipolar Depression: Core neurochemical deficit in \(5\text{-HT}\) and Noradrenaline; structural loss in Hippocampus and reduced BDNF. Key treatments: SSRIs (block SERT), SNRIs, CBT.
• Schizophrenia: Mesolimbic dopamine excess (\(D_2\) \(\rightarrow\) Positive symptoms); Mesocortical dopamine deficit (\(\rightarrow\) Negative symptoms). Structural markers: Ventriculomegaly and gray matter loss. Treatments: Typical antipsychotics (\(D_2\) antagonists) and Atypical antipsychotics (\(D_2\) and \(5\text{-HT}_{2A}\) antagonists).
• Alzheimer's Disease: Neuropathology includes extracellular \(\text{A}\beta\) plaques, intracellular hyperphosphorylated tau tangles, and loss of ACh neurons in the nucleus basalis of Meynert. Treatments: Acetylcholinesterase inhibitors (Donepezil) and NMDA antagonists (Memantine).